L M Refolo

Summary

Affiliation: Nathan Kline Institute
Country: USA

Publications

  1. ncbi request reprint Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model
    L M Refolo
    Nathan S Kline Institute for Dementia Research, Orangeburg, New York, USA
    Neurobiol Dis 7:321-31. 2000
  2. ncbi request reprint A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease
    L M Refolo
    Nathan S Kline Institute for Psychiatric Research, Orangeburg, New York 10962, USA
    Neurobiol Dis 8:890-9. 2001
  3. ncbi request reprint Modulation of A(beta) peptides by estrogen in mouse models
    H Zheng
    Huffington Center on Aging, Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA
    J Neurochem 80:191-6. 2002
  4. ncbi request reprint Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology
    M A Pappolla
    University of South Alabama, Mobile, USA
    Neurology 61:199-205. 2003
  5. ncbi request reprint A new pathogenic mutation in the APP gene (I716V) increases the relative proportion of A beta 42(43)
    C B Eckman
    Mayo Clinic Jacksonville, 4500 San Pablo Road, Jacksonville, FL 32224, USA
    Hum Mol Genet 6:2087-9. 1997
  6. ncbi request reprint New directions in neuroprotection: basic mechanisms, molecular targets and treatment strategies
    L M Refolo
    J Alzheimers Dis 6:S1-2. 2004

Collaborators

Detail Information

Publications6

  1. ncbi request reprint Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model
    L M Refolo
    Nathan S Kline Institute for Dementia Research, Orangeburg, New York, USA
    Neurobiol Dis 7:321-31. 2000
    ..These data demonstrate that high dietary cholesterol increases Abeta accumulation and accelerates the AD-related pathology observed in this animal model. Thus, we propose that diet can be used to modulate the risk of developing AD...
  2. ncbi request reprint A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease
    L M Refolo
    Nathan S Kline Institute for Psychiatric Research, Orangeburg, New York 10962, USA
    Neurobiol Dis 8:890-9. 2001
    ..This study demonstrates that hypocholesterolemia is associated with reduced Abeta accumulation suggesting that lowering cholesterol by pharmacological means may be an effective approach for reducing the risk of developing AD...
  3. ncbi request reprint Modulation of A(beta) peptides by estrogen in mouse models
    H Zheng
    Huffington Center on Aging, Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA
    J Neurochem 80:191-6. 2002
    ..These results provide evidence that post-menopausal estrogen depletion may be linked to an increased risk of AD through A(beta) modulation...
  4. ncbi request reprint Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology
    M A Pappolla
    University of South Alabama, Mobile, USA
    Neurology 61:199-205. 2003
    ..Epidemiologic and experimental data suggest that cholesterol may play a role in the pathogenesis of AD. Modulation of cholesterolemia in transgenic animal models of AD strongly alters amyloid pathology...
  5. ncbi request reprint A new pathogenic mutation in the APP gene (I716V) increases the relative proportion of A beta 42(43)
    C B Eckman
    Mayo Clinic Jacksonville, 4500 San Pablo Road, Jacksonville, FL 32224, USA
    Hum Mol Genet 6:2087-9. 1997
    ....
  6. ncbi request reprint New directions in neuroprotection: basic mechanisms, molecular targets and treatment strategies
    L M Refolo
    J Alzheimers Dis 6:S1-2. 2004